Table 1 Characteristics of the eligible trials included in the systems assessment.
Author | Year | Phase | Country | Treatments of experimental and control group | No. of | CR+PR | OS | PFS | TTP |
|---|---|---|---|---|---|---|---|---|---|
patients | (%) | (m) | (m) | (m) | |||||
Auliac et al. | 2014 | II | Global | docetaxel 75 mg/m2 d1, erlotinib 150 mg d2-16 | 73 | 12.30 | 6.5 | 2.2 | — |
(GFPC 10.02)19 | |||||||||
docetaxel 75 mg/m2 d1 | 74 | 6.60 | 8.3 | 2.5 | — | ||||
Chen et al.4 | 2007 | II | China | Vinorelbine 15 mg/m2 D1; gefitinib 250 mg/d, D2–14 | 21 | 52.38 | 23.4 | — | 12.8 |
Gefitinib 250 mg/d | 27 | 55.56 | 13.3 | — | 7.1 | ||||
Guo et al.20 | 2012 | II | China | gemcitabine1250 mg/m2 on days 1 and 8, cisplatin 25 mg/m2, gefitinib 250 mg/d days 10–24 | 36 | 36.10 | 12.1 | 7.3 | — |
gemcitabine1250 mg/m2 on days 1 and 8,cisplatin 25 mg/m2 | 35 | 14.30 | 10.8 | 5.8 | — | ||||
Jia et al.22 | 2014 | II | China | pemetrexed 500 mg/m2 day 1 or docetaxel 75 mg/m2 d1, gefitinib 250 mg/d days 2–20 | 33 | 9.10 | 10.4 | 4.2 | — |
pemetrexed 500 mg/m2 day 1 or docetaxel 75 mg/m2 d1, | 33 | 6.45 | 7.9 | 3.3 | — | ||||
Lee et al.16 | 2013 | II | Global | Pemetrexed 500 mg/m2 D1; erlotinib 150 mg/d D2–14 | 78 | 44.74 | 20.5 | 7.4 | — |
Pemetrexed, 500 mg/m2 D1 | 80 | 10. 00 | 17.7 | 4.4 | — | ||||
erlotinib 150 mg daily | 82 | 29.27 | 22.8 | 3.8 | |||||
Mok et al. (FAST-ACT)3 | 2009 | II | Asian Pacific | Gemcitabine 1250 mg/m2 D1 & 8; cisplatin 75 mg/m2 D1 or carboplatin AUC 5 D1; erlotinib 150 mg/d, D15–28 | 76 | 35.55 | 17.29 | 6.86 | — |
Gemcitabine 1250 mg/m2 D1 & 8; cisplatin 75 mg/m2 or carboplatin AUC 5 D1 | 78 | 24.36 | 17.66 | 5.46 | — | ||||
Yu et al.21 | 2014 | II | China | pemetrexed 500 mg/m2 day 1,ciplatin 75 mg/m2 or carboplatin AUC = 5, gefitinib 250 mg/d days 3–16 | 58 | 50.00 | 25.4 | 7.9 | — |
pemetrexed 500 mg/m2 day 1,ciplatin 75 mg/m2 or carboplatin AUC = 5 | 59 | 47.40 | 20 | 7 | — | ||||
Wu et al. (FASTACT-2)15 | 2013 | III | Asia | Gemcitabine 1250 mg/m2 D1 & 8; carboplatin AUC 5 or cisplatin 75 mg/m2 D1; erlotinib 150 mg/d D15–28 | 226 | 42.92 | 18.3 | 7.6 | — |
Gemcitabine 1250 mg/m2 D1 & 8; carboplatin AUC 5 or cisplatin 75 mg/m2 D1 | 225 | 18.22 | 15.2 | 6 | — | ||||
Hirsch et al.17 | 2011 | II | Global | Paclitaxel 200 mg/m2; carboplatin AUC 6; erlotinib 150 mg, D2–15 | 67 | 22.38 | 11.43 | 4.57 | — |
Erlotinib 150 mg/d | 69 | 11.59 | 16.7 | 2.69 | — | ||||
Aerts et al. (NVALT-10)18 | 2013 | II | Netherlands | Erlotinib 150 mg D2–16; docetaxel 75 mg/m2 D1 or pemetrexed 500 mg/m2 D1 | 116 | 12.93 | 7.8 | 6.1 | — |
Erlotinib 150 mg/d | 115 | 6.96 | 5.5 | 4.9 | — |
